Canadian (TSX) Clinical Research and Equipment Industry Analysis
UpdatedMay 26, 2022
DataAggregated Company Financials
Companies5
- 7D1.9%
- 3M-6.0%
- 1Y-30.1%
- YTD-29.8%
In the last week, the Clinical Research and Equipment industry is up 1.9%, with ImmunoPrecise Antibodies up 10%. During this same period, the Telescope Innovations underperformed, falling 56%. In the past year, the industry is down 30%. Looking forward, earnings are forecast to grow by 26% annually.
Industry Valuation and Performance
Has the Canadian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Sat, 28 May 2022 | CA$196.7m | CA$21.5m | -CA$26,635,227.00 | 15.9x |
| Mon, 25 Apr 2022 | CA$237.3m | CA$21.6m | -CA$23,635,914.00 | 25.9x |
| Wed, 23 Mar 2022 | CA$168.1m | CA$21.6m | -CA$23,635,914.00 | 25.9x |
| Fri, 18 Feb 2022 | CA$194.1m | CA$21.3m | -CA$21,103,914.00 | 27.3x |
| Sun, 16 Jan 2022 | CA$251.4m | CA$20.9m | -CA$20,076,847.00 | 30x |
| Tue, 14 Dec 2021 | CA$239.9m | CA$21.0m | -CA$14,997,109.00 | 25.9x |
| Thu, 11 Nov 2021 | CA$259.1m | CA$21.0m | -CA$14,997,109.00 | 24.6x |
| Sat, 09 Oct 2021 | CA$249.3m | CA$20.7m | -CA$14,899,797.00 | 25.2x |
| Mon, 06 Sep 2021 | CA$248.4m | CA$20.7m | -CA$11,409,216.00 | 21.1x |
| Wed, 04 Aug 2021 | CA$243.2m | CA$20.7m | -CA$11,409,216.00 | 19.1x |
| Sat, 08 May 2021 | CA$239.1m | CA$19.3m | -CA$7,096,150.00 | 27.1x |
| Tue, 09 Feb 2021 | CA$373.7m | CA$18.4m | -CA$3,146,070.00 | 68.4x |
| Mon, 02 Nov 2020 | CA$180.4m | CA$17.7m | -CA$2,528,358.00 | 134.5x |
| Thu, 06 Aug 2020 | CA$113.0m | CA$16.0m | -CA$3,506,338.00 | n/a |
| Sun, 10 May 2020 | CA$53.3m | CA$14.1m | -CA$4,947,000.00 | n/a |
| Sat, 01 Feb 2020 | CA$70.5m | CA$13.6m | -CA$24,476,059.00 | n/a |
| Tue, 05 Nov 2019 | CA$84.9m | CA$13.1m | -CA$22,948,478.00 | 145x |
| Fri, 09 Aug 2019 | CA$95.7m | CA$11.7m | -CA$22,704,312.00 | n/a |
Median PE Ratio
n/a
Current Industry PEThere is only one profitable company in this industry, so there is insufficient data to make an industry-wide assessment of PE.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 22% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does Canadian Clinical Research and Equipment compare with similar industries?
| CA Market | 1.68% | |
| Healthcare | 0.16% | |
| Life Sciences | 1.89% | |
| Clinical Research and Equipment | 1.89% | |
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| IPA ImmunoPrecise Antibodies | CA$6.80 | 13.3% +CA$18.8m | -28.6% | PS8.4x | |
| DOSE Rapid Dose Therapeutics | CA$0.21 | 5.0% +CA$1.0m | 0% | PS21.1x | |
| LEXT Lexston Life Sciences | CA$0.098 | 30.0% +CA$263.7k | n/a | n/a |